What is GBM?
Glioblastoma (GBM) is the deadliest type of brain cancer, accounting for 45% of all malignant brain tumors. In the United States alone, over 12,000 new cases per year are detected. The disease has long been universally fatal and without cure, with a median survival rate after diagnosis of one to two years and killing 95% of patients within five years.
GBM AGILE IS CHANGING THE IDEA OF CLINICAL TRIALS
Innovative – Next-generation trial that will lower cost of development and speed progress.
Dynamic – Perpetual learning system to quickly add potentially promising new drugs and drop those that appear to be ineffective.
Efficient –Design and trial structure that will require fewer patients and a shorter time frame to get important answers about a drug’s effectiveness
Accessible – Global effort open to a broad patient population of newly diagnosed and recurrent GBM patients.
